Merck & Co., Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Merck & Co., Inc. (MRK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.62 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-24
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-09-30 was 0.00 shares.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-09-30 was 0.00 shares.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.62M shares, a 7.82% decline from fiscal 2024.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.75M shares, a 4.00% decline from fiscal 2023.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.83M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 1.62M shares 10-K · filed 2026-02-24 | |||
| 2024-12-31 | 1.75M shares 10-K · filed 2025-02-25 | |||
| 2023-12-31 | 1.83M shares 10-K · filed 2024-02-26 | |||
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 4.00M shares 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | 4.00M shares 10-Q · filed 2020-08-05 | |||
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 3.00M shares 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | 3.00M shares 10-Q · filed 2020-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |